---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-25-000025"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:16:33.515761+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AEON CEO Marc Forth resigns; Chairman Jost Fischer named interim CEO

## Summary
- Marc Forth steps down as President and CEO effective April 4, 2025, to pursue another opportunity.
- Forth remains on the board; departure is not due to any disagreement with AEON.
- Chairman Jost Fischer appointed Interim CEO; board actively seeking permanent replacement.
- AEON expects current cash to fund through Biosimilar BPD Type 2a meeting with FDA in H2 2025.
- AEON is a clinical-stage biopharma developing botulinum toxin complex ABP-450 as a BOTOX biosimilar.

## SEC filing metadata
- accession: 0001837607-25-000025
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000025/0001837607-25-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000025/aeon-20250324x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-25-000025
- JSON: https://secwatch.observer/filing/0001837607-25-000025.json
- Plain text: https://secwatch.observer/filing/0001837607-25-000025.txt

## Key facts
- Executive change
  Jost Fischer was appointed as Interim Chief Executive Officer at AEON Biopharma, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: The Board has named Jost Fischer, the current Chairman of the Board, to serve as Interim CEO following Mr. Forth’s departure while the Board identifies a replacement CEO.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000025/0001837607-25-000025-index.htm
- Executive change
  Marc Forth resigned as President and Chief Executive Officer at AEON Biopharma, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: On March 24, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) was notified by Marc Forth that he intended to resign as the Company’s President and Chief Executive Officer (“CEO”) in order to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000025/0001837607-25-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.